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ABSTRACT
The microRNA, miR-200c, is involved in the tumorigenesis and progression of 
a variety of cancers. The purpose of this study was to investigate the expression, 
mechanism and prognostic roles of miR-200c in breast cancer. We found that miR-
200c was downregulated in both breast cancer tissue and cell lines using quantitative 
real-time PCR (qRT-PCR). In situ hybridization (ISH) and microarrays showed that 
low miR-200c expression was associated with poor patient overall survival (OS) and 
disease free survival (DFS). We used luciferase reporter plasmids to find that miR-
200c inhibited the AKT and ERK pathways by directly targeting KRAS. Repression of 
KRAS by miR-200c suppressed the proliferation and survival of breast cancer cells 
in vitro and in vivo. miR-200c also had an anti-tumor effect by negatively regulating 
KRAS in a xenograft mouse model. Our findings provide clues regarding the role of 
miR-200c as a tumor suppressor in breast cancer through the inhibition of KRAS 
translation both in vitro and in vivo. miR-200c could be a potential therapeutic target 
in breast cancer.
INTRODUCTION
Breast cancer is the most common cancer and 
holds the highest mortality in females worldwide [1]. 
Breast cancer is a heterogeneous disease. According to 
its molecular subtype, breast cancer can be classified into 
different categorizations that provide an efficient path for 
comprehensive therapy and prognosis [2]. Specifically, 
these types are luminal A type (ER+ and/or PR+, HER2-), 
luminal B type (ER+ and/or PR+, HER2+), HER2 over-
expressing type (ER−, PR−, and HER2+) and basal-like 
type (ER-, PR-, HER2-, cytokeratin 5/6+, and/or EGFR+) 
[3]. Although the detection and treatment of breast cancer 
has greatly improved, prognosis for most patients is still 
poor [4].
MicroRNAs (miRNAs) are small single-stranded 
RNAs that have various vital biological functions [5]. 
They are highly conserved and specific, regulating 
gene expression by binding to the 3′-untranslated region 
(3′-UTR) of target messengerRNAs (mRNAs) and either 
inhibiting translation or inducing degradation of mRNAs 
[6]. The microRNA-200 (miR-200) family consists of 
miR-200a, miR-200b, miR-200c, miR-141 and miR-429, 
which all have the same seed sequence and homologous 
targets. The miR-200 family can regulate the epithelial- 
to-mesenchymal transition (EMT) and enhance the 
reverse of this process [7]. The dysregulation of the miR-
200 family is involved in several malignancies, such as 
gastric [8, 9], breast [10], bladder [11], and lung [12] 
cancer. Among all the miR-200 family members, miR-
200c is considered to play an important role in EMT [13] 
and cancer chemo-sensitivity [14, 15]. By regulating a 
multitude of oncogenic pathways, miR-200c is a potent 
inhibitor of tumor progression and therapy resistance [16]. 
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However, the prognostic role of miR-200c in breast cancer 
is not completely known.
RAS is a small gene family known for its ability 
to cause neoplasia. There are three ras genes that have 
been identified in the mammalian genome, designated 
HRAS, KRAS and NRAS [17]. RAS can be activated 
by retroviral insertional mutagenesis which has been 
described in the origin of avian [18] and mammalian [19] 
tumors. The genetic mutation of intracellular effectors that 
are involved in GTPase-related signaling pathways usually 
have an effect on the response of the targeted therapy 
[20]. Recently, KRAS mutations have been reported to 
be involved in human cancer, including nasopharyngeal 
carcinoma [21], ovarian cancer [22], lung cancer [23], 
pancreatic cancer [24], oral squamous cell carcinoma 
[25], esophageal squamous cell carcinoma [26], colorectal 
cancer [27] , breast cancer [28] and so on.
Although abnormal expression of miRNA and 
KRAS has been associated with tumorigenesis in human 
breast cancer, we still know little about how miRNAs act 
on KRAS. In this study, we investigated the expression of 
miR-200c and its potential prognostic role in breast cancer 
patients. We predicted and verified KRAS as a target of 
miR-200c in breast cancer. Furthermore, we confirmed 
that miR-200c could inhibit KRAS expression and 
suppress the proliferation and clone formation of breast 
cancer cells in vitro. miR-200c over-expression could 
inhibit the tumor formation and growth in vivo.
RESULTS
miR-200c is downregulated in breast cancer cell 
lines and clinical specimens
miR-200c is reported to be downregulated in 
many cancers, including gastric cancer [29], renal cell 
carcinoma [30], ovarian cancer [31] and so on. qRT-PCR 
analysis was used to detect the expression of miR-200c 
in 12 different mammary cell lines, including human 
mammary epithelial (HME) cell lines (MCF-10A, 184A1, 
BHL-100), human breast cancer cell lines (T47D, BT-474, 
MCF-7, BT-483, MDA-MB-468, BT-20, MDA-MB-435, 
MDA-MB-231) and mouse breast cancer cell line 4T1. 
Compared with HME cell lines, we found that miR-200c 
was downregulated in human and mouse breast cancer cell 
lines, especially in BT-20, MDA-MB-435, MDA-MB-231 
and 4T1 (Figure 1A). We chose MDA-MB-231 and 4T1 
for further studies.
Then, we detected the expression of miR-200c and 
KRAS in 41 pairs of breast cancer tissues (BC) and their 
matched normal adjacent tissues (CTR). Among 41 breast 
cancer patients, approximately 80% (P < 0.0001, 33 of 
41 patients) of tumor samples revealed reductions in 
miR-200c levels (Figure 1B). As show in Supplement 
Figure S1, 87.8% (P < 0.0001, 36 of 41 patients) of tumor 
samples revealed an increase in the expression levels of 
KRAS. Furthermore, statistical analysis revealed that 
miR-200c levels in 41 breast cancer tumors samples were 
significantly inversely correlated with the expression of 
KRAS (r = −0.64, P < 0.001; Supplement Figure S2). 
These results indicate that downregulation of miR-200c 
is a frequent event in breast cancer clinical specimens and 
could be related to the carcinogenesis of breast cancer.
Decreased miR-200c levels are correlated with 
clinical stage, relapse, metastasis and poor 
clinical outcomes
We explored the potential clinicopathological 
implications arising from altered miR-200c levels. The 
tissue microarrays (TMAs) of 134 breast cancer samples 
were used for in situ hybridization analysis. These clinical 
samples were divided into low or high expression groups 
based on miR-200c expression scores less or greater than 2 
(Table 1). We found that miR-200c levels were inversely 
correlated with clinical stage, local relapse and distant 
metastasis (P = 0.017, 0.019 and 0.033 respectively) 
(Table 1) but not correlated with age, menopause, tumor 
size, lymph node metastasis, ER, PR, HER2 and P53 
status among the 134 breast cancer patients. These results 
revealed that miR-200c might play a vital role in the 
occurrence and progression of breast cancer.
To explore the significance of miR-200c in clinical 
prognosis, we used Kaplan-Meier survival analysis to 
make patient overall survival (OS) and disease free 
survival (DFS) curves. The results demonstrated that 
patients with low miR-200c expression had shorter mean 
months of OS and DFS than patients with high expression 
(P = 0.001 for OS, P = 0.002 for DFS, Figure 2A and 
2B). These results demonstrate that miR-200c expression 
is significantly associated with patient OS and DFS.
miR-200c inhibits the AKT and ERK pathways 
by targeting KRAS
To explore the function of miR-200c, we used 
computational algorithms (Targetscan and Miranda) to 
identify the potential target gene of miR-200c in human 
breast cancer. The algorithm predicted that KRAS was 
a target gene of miR-200c (Figure 3A). We performed 
luciferase reporter assays to clarify this finding. The 
full-length KRAS was cloned downstream of the firefly 
luciferase gene and cotransfected with miR-200c mimics 
or scrambled oligonucleotides controls (The transfection 
of miR-200c or scramble was successful, Supplement 
Figure S3). Luciferase activity was measured 48 hours after 
transfection. We found that the luciferase expression was 
decreased in MDA-MB-231 cells that were co-transfected 
with miR-200c and the wild-type KRAS 3′-UTR, compared 
to controls. However, no decrease can be observed in cells 
which were co-transfected with miR-200c and the mutant 
KRAS 3′-UTR in comparison with controls (Figure 3B). 
These results suggest that miR-200c can directly target 
KRAS.
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To determine the level at which miR-200c influences 
KRAS expression, we examined the expression of KRAS 
mRNA after transfection with miR-200c mimics or 
scramble doligonucleotides controls in MDA-MB-231 
and 4T1 cells. After transfection with miR-200c mimics, 
the expression of KRAS mRNA in two cell lines was 
lower than in the controls (Figure 3C). The effect of miR-
200c on KRAS expression was also verified by Western 
blotting analyses. The over-expression of miR-200c 
reduced KRAS protein levels significantly (Figure 3D). 
These results provide evidence that miR-200c directly 
recognizes the 3′-UTR of KRAS mRNA and inhibits 
KRAS translation.
The activation of KRAS can trigger several 
significant pathways, including the AKT and ERK 
pathways [32, 33]. Therefore, we presumed that miR-200c 
might regulate those pathways by targeting KRAS. Then 
we upregulated miR-200c levels via miR-200c mimics 
in MDA-MB-231 and 4T1 cells. Western blot results 
demonstrate that miR-200c decreased the phosphorylation 
levels of AKT and ERK and negatively regulated the 
pathways (Figure 3E, quantification of protein levels are 
supplied in Supplement Figure S4).
Subsequently, we treated 4T1 cells with miR-200c 
or scramble control. 24 hours later we transfected them 
with KRAS-encoding vector (without an endogenous 
3′-UTR) or mock vector (Figure 3F showed that the 
transfection was successful in both MDA-MB-231 and 
4T1 cells). The miR-200c mimic induced downregulation 
of KRAS, then the downregulation was rescued by the 
introduction of KRAS. A similar alteration was observed 
in the phosphorylation levels of AKT and ERK. The 
downregulation of phosphorylated AKT and ERK by 
miR-200c could also be rescued by re-expression of 
KRAS in 4T1 cells (Figure 3G; quantification of protein 
levels are supplied in Supplement Figure S5). These 
results suggest that miR-200c inhibits the AKT and ERK 
pathways by targeting KRAS.
miR-200c inhibits the proliferation and colony 
formation of breast cancer by targeting KRAS
To analyze the biological consequences of the 
miR-200c-driven repression of KRAS in breast cancer 
cells, we investigated whether increasing or decreasing 
the expression of miR-200c would have an impact on cell 
proliferation and clone formation in MBA-MD-231 and 
4T1 cells.
MDA-MB-231 and 4T1 cells were transfected with 
miR-200c mimics, miR-200c inhibitors or their scrambled 
oligonucleotides controls respectively (The transfection 
were successful, see in Supplement Figure S3) and 
counted after 24 hours. The proliferation assay showed 
that the increased expression of miR-200c in MDA-
MB-231 and 4T1 cells attenuated proliferation compared 
with the control cells, while the decreased expression of 
miR-200c promoted proliferation (Figure 4A). Moreover, 
increased expression of miR-200c inhibited the ability to 
form clones in soft agar (Figure 4B). We then decided to 
evaluate the effect of miR-200c over-expression on tumor 
formation and growth in vivo by adopting a xenograft 
model of breast cancer cells in BALC/c mice. 4T1 cells 
infected with recombinant lentiviruses containing 
miR-200c precursor or scrambled sequences were 
Figure 1: miR-200c is downregulated in breast cancer cell lines and clinical specimens. A. Expression levels of miR-200c 
determined by qRT-PCR in 12 different mammary cell lines, including 3 human mammary epithelial cell lines, 8 human breast cancer cell 
lines and 1 mouse breast cancer cell line. miR-200c expression was normalized using U6 RNA expression. B. Expression levels of miR-
200c in 41 pairs of breast cancer tissues (BC) and their matched normal adjacent tissues (CTR). All of the data are shown as the means  
± s.e.m. **P < 0.01.
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Table 1: Clinicopathological variables and miR-200c expression in 134 breast cancer patients
Characteristics Total(n = 134)
miR-200c low
(n = 83)
miR-200c high
(n = 51)
P value
No. % No. %
OS 0.001*
  Present 107 59 55.1 48 44.9
 Absent 27 24 88.9 3 11.1
DFS 0.002*
 Present 96 53 55.2 43 44.8
 Absent 38 30 78.9 8 22.1
Age (years) 0.397
 <50 82 52 63.4 30 36.6
 > =50 52 31 59.6 21 42.3
Menopause 0.294
 Yes 63 37 58.7 26 41.3
 No 71 46 64.8 25 35.2
Tumor size (cm) 0.491
 = <2 38 23 60.5 15 39.5
 >2 96 60 62.5 36 37.5
LNMET 0.076
 Yes 80 54 67.5 26 32.5
 No 54 29 53.7 25 46.3
TNM stage 0.017*
 I–II 78 42 53.8 36 46.2
 II– IV 56 41 73.2 15 26.8
Local relapse 0.019*
 Yes 8 8 100.0 0 0
 No 126 75 59.5 51 40.5
Distant metastasis 0.033*
 Yes 34 26 76.5 8 23.5
 No 100 57 57.0 43 43.0
ER status 0.222
 Positive 51 29 56.9 22 43.1
 Negative 83 54 65.1 29 34.9
PR status 0.099
 Positive 55 30 54.5 25 45.5
 Negative 79 53 67.1 26 32.9
(Continued )
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subcutaneously injected into flank BALC/cmice (five in 
each group). The tumor volume was measured every four 
days after injection and accordingly the growth curves of 
the tumors were plotted. All mice were later sacrificed 
to harvest the xenograft. The mean volume and weight 
of tumors was reduced in the miR-200c overexpressing 
group compared with the control group (Figure 4C).
The above results prompted us to validate that 
miR-200c could indeed inhibit the proliferation of breast 
cancer by repressing KRAS expression. For this purpose, 
MDA-MB-231 and 4T1 cells were transfected with mock 
vector, scrambled oligonucleotides controls, KRAS-
encoding vector + miR-200c or mock vector + scrambled 
oligonucleotides controls respectively. The results 
show that increased expression of miR-200c inhibited 
proliferation by repressing KRAS (Figure 4D).
DISCUSSION
The functional microRNA, miR-200c, plays a 
significant role in many human cancers. Previous research 
reports that miR-200c is markedly downregulated in many 
cancer cells and tissues and inhibits cancer proliferation 
and migration [34, 35]. However, few researchers 
have focused on the expression of miR-200c and its 
biological function in breast cancer. In this study, through 
measuring the expression of miR-200c in breast cancer 
cell lines, human breast cancer tissues and their matched 
normal adjacent tissues, we found that miR-200c was 
downregulated in breast cancer. We discovered potential 
clinicopathological implications of miR-200c by analyzing 
the correlation of miR-200c levels with clinical stage, 
local relapse and distant metastasis. This is the first report 
about the clinicopathological implications arising from 
altered miR-200c levels in breast cancer.
We then predicted that KRAS was a target of miR-
200c, which is a member of miR-200 family and usually 
known to function as tumor suppressors in many cancers [8, 
9, 29]. miRNAs regulate gene expression by binding to the 
3’-UTR of target mRNAs and either inhibiting translation or 
inducing degradation of mRNAs [6]. That’s to say, miRNAs 
exert the regulation function via mRNAs or protein levels. 
Characteristics Total(n = 134)
miR-200c low
(n = 83)
miR-200c high
(n = 51)
P value
No. % No. %
HER-2 status 0.529
Positive 22 14 63.6 8 36.4
Negative 112 69 61.6 43 38.4
P53 status 0.156
Positive 77 51 66.2 26 33.8
Negative 57 32 56.1 25 43.9
*means statistically significant (P < 0.05).
%means percentage within the row.
Figure 2: Decreased miR-200c levels are correlated with clinical stage, local relapse, distant metastasis and poor 
clinical outcomes. A. Low levels of miR-200c correlated with shorter survival. OS curves for 134 studied patients with high or low miR-
200c expression. B. DFS curves for 134 studied patients with high or low miR-200c expression.
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In this study, we first detect that miR-200c levels have an 
inverse correlation with both KRAS protein levels and 
KRAS mRNA levels.
Furthermore, by over-expressing miR-200c in 
MDA-MB-231 and 4T1 cells, we validated that miR-
200c can directly inhibit the AKT and ERK pathways 
by directly targeting KRAS and inhibiting its translation. 
The miR-200c-mimic induced downregulation of KRAS, 
along with decreased levels of phosphorylated AKT and 
phosphorylated ERK, were rescued with the introduction 
of KRAS. At last, we provide evidence that miR-200c 
can inhibit the proliferation and clone formation of 
breast cancer in vitro by targeting KRAS. These results 
delineated a novel regulatory network employing miR-
200c and KRAS to fine-tune cell proliferation and clone 
formation. Further, the mechanism in which miR-200c 
exerts its tumor suppressive function is by targeting 
KRAS. Therefore, the modulation of KRAS by miR-
200c may explain why the downregulation of miR-
200c during breast carcinogenesis can promote cancer 
progression.
In summary, low miR-200c expression levels are 
associated with poor DFS and OS in breast cancer patients. 
miR-200c inhibits the AKT and ERK pathways by directly 
targeting KRAS. We also provide evidence about the 
biological effects of overexpression of miR-200c in breast 
cancer. We further demonstrate that miR-200c functions as 
a tumor suppressor in breast cancer by in vitro and in vivo 
models. Therefore, miR-200c is a valuable marker for 
breast cancer progression and prognosis.
Figure 3: miR-200c inhibits the AKT and ERK pathways by targeting KRAS. A. miR-200c bound to the 3′-UTRs of KRAS. 
Predicted binding between miR-200c and the seeds matched in the 3′-UTRs of predicted genes. B. Luciferase assay of MDA-MB-231 and 
4T1 cells cotransfected with miR-200c mimics, a scrambled control and a luciferase reporter containing KRAS 3′-UTR (KRAS-wt) or 
mutant constructs in which the first four nucleotides of the miR-200c binding site were mutated (KRAS-mut). All of the data are shown 
as the means ± s.e.m. *P < 0.05. C. MDA-MB-231 and 4T1 cells were transfected with miR-200c or scramble in control. miR-200c 
overexpression inhibited the KRAS mRNA expression. All of the data are shown as the means ± s.e.m. ** P < 0.01. D. MDA-MB-231 
and 4T1 cells were transfected with miR-200c or scramble in control. miR-200c overexpression inhibited the protein expression of KRAS. 
E. MDA-MB-231 and 4T1 cells were transfected with miR-200c or scramble in control. miR-200c overexpression inhibited the activity 
of AKT and ERK pathway. F. The transfection of KRAS was successful. All of the data are shown as the means ± s.e.m. ** P < 0.01. 
G. miR-200c/scramble control transfection followed by KRAS/mock vector transfection 24 hours later in 4T1 cells affected AKT and ERK 
signalling. The protein expression levels of phosphorylated AKT (pAKT) and ERK (pERK) were measured to examine the activity of AKT 
and ERK pathways. The miR-200c-induced downregulation of KRAS was rescued by the introduction of KRAS. A similar alteration was 
observed in the phosphorylation levels of AKT and ERK.
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MATERIALS AND METHODS
Human tissue
All the tissue samples in this study were collected 
from the Sun Yat-Sen University Cancer Center 
(Guangzhou, Guangdong, China) and used according 
to the ethical standards as formulated in the Helsinki 
Declaration. All the aspects of this study were approved by 
the Ethics Committee of Sun Yat-Sen University Cancer 
Center Health Authority.
Tissue samples from 41 breast cancer patients 
were subjected to qRT-PCR analysis. TMAs composed 
of 134 cases of breast cancer were used for in situ 
hybridization analysis, and all of them were confirmed by 
histopathology diagnosis during the period from October 
2001 to September 2006. Resected breast cancer tissues 
(BC) and paired matched normal mammary tissues (CTR) 
were immediately cut and stored in RNAlater (Ambion). 
Specimens were obtained during surgery and stored in the 
Department of Specimens and Resources of Sun Yat-Sen 
University Cancer Center which were formalin fixed and 
embedded in paraffin following the standard methods.
All the clinical data of patients such as age, 
histologic type, tumor size, lymph node status, local or 
distant metastatic relapse, ER status, PR status and HER2 
status were available and reviewed. Histologic type was 
determined on TNM staging system which was classified 
Figure 4: miR-200c inhibits the proliferation and clone formation of breast cancer by targeting KRAS. A. MDA-MB-231 
and 4T1 cells were transfected withmiR-200c mimics, miR-200c inhibitors or their scrambled oligonucleotides controls. The proliferation 
of cells was assayed. All of the data are shown as the means ± s.e.m. **P < 0.01. B. MDA-MB-231 and 4T1 cells were transfected with 
scramble or miR-200c. Clone formation of cells was examined. Numbers of colonies are showed as the means ± s.e.m. **P < 0.01. 
C. Tumor growth in mouse xenograft models. 4T1 cells transfected with recombinant lentiviruses containing miR-200c precursor or 
scramble sequences were injected subcutaneously into BALC/c mice (five in each group). The tumor volume was measured every four 
days. After 28 days, the mice were killed, necropsies were performed, and the tumors were weighed. All of the data are shown as the means 
± s.e.m. **P < 0.01. D. MDA-MB-231 and 4T1 cells were transfected with mock vector, scrambled oligonucleotides controls, KRAS-
encoding vector + miR-200c or mock vector + scrambled oligonucleotides controls respectively. The proliferation of cells was assayed. All 
of the data are shown as the means ± s.e.m. **P < 0.01.
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according to the WHO classification and tumor stage 
(American Joint Committee on Cancer classification). No 
patient had ever received any chemotherapy or radiation 
therapy before the surgery or in the present study. Follow-
up included the review of records and telephone calls, and 
the length of follow-up was 70 months. The dates of death 
and relapse were used to calculate DFS and OS. DFS was 
calculated from diagnosis to disease progression or death, 
no matter which occurred first. Patients who were alive 
and disease free were censored at the date of last follow-
up visit. Distant met referred to the cancer which spread 
to the whole tissues or organs, mainly including bone, 
lung and brain. OS was the time from diagnosis to the 
date of death for any cause, and patients who were alive 
were censored at date of last follow-up visit. The patients 
were grouped according to their clinical features listed in 
Table 1.
In situ hybridization (ISH) analysis
In situ hybridization procedures were carried out as 
previously described [36]. miR-200c miRCURYTM LNA 
custom detection probes (Exiqon, Vedbaek, Denmark) 
were used for ISH. The 5′-3′ sequences (enhanced with 
LNA) were TCCATCATTACCCGGCAGTATTA with 
a DIG label at both the 5′ and 3′ ends. Hybridization, 
washing, and scanning were carried out according to the 
manufacturer’s instructions. The intensities of miR-200c 
staining was scored by 0–4, according to the standards 
of 0–1 (no staining), 1–2 (weak staining), 2–3 (medium 
staining) and 3–4 (strong staining). The percentages 
of miR-200c cells in three representative high-power 
fields of individual samples were analyzed. Those 
expression scores equaled to scores of the intensities × the 
percentages of positive cells, and the maximum was 4 and 
the minimum was 0. Every samples were assessed by 
at least two pathologists in a blinded manner, and those 
expression scores of greater or equal to 2 was defined as 
high expression, less than 2 was low expression [37].
Cell culture
The human breast cancer cell line MBA-MD-231 
and mouse breast cancer cell line 4T1 were purchased 
from the Shanghai Institute of Cell Biology, Chinese 
Academy of Sciences (Shanghai, China). MBA-MD-231 
and 4T1 cells were cultured in DMEM (Gibco, USA) 
supplemented with 10% fetal bovine serum (Gibco) in a 
humidified incubator at 37°C with 5% CO2.
Quantitative real-time PCR analysis (qRT-PCR)
Total RNA from tissues and the cultured cells 
was extracted with the TRIzol reagent (Invitrogen, 
USA). Reverse transcription and qRT-PCR reactions 
were performed using a qSYBR-Green-containing PCR 
kit (Qiagen, USA) and a BioRad IQTM5 Multicolor 
Real-Time PCR Detection System (USA). The equation 
2− ΔΔCt was used to calculate the relative amount of 
miRNA among Which U6 snRNA was used as an internal 
control (Ct was the fractional cycle number at which the 
fluorescence of each sample passes the fixed threshold) 
and ΔΔCT = (CT miRNA − CT U6)target − (CT miRNA − CT U6)control. 
The primers of KRAS mRNA for qRT-PCR detection were 
as follows: forward, 5′-GGACTGGG-GAGGGCTTTCT-3′ 
and reverse, 5′-GCCTGTTTTGTGTCTACTGTTCT-3′. 
The primer was synthesized by Invitrogen. Each 
experiment was performed three times intriplicate.
miRNA overexpression
miRNA mimic (a synthetic RNA oligonucleotide 
duplex mimicking miRNA precursor) was used for 
the overexpression of miRNA. The synthetic RNA 
molecules were purchased from GenePharma (Shanghai, 
China) including pre-miR-200c and pre-miR-control 
(scrambled negative control RNA). MDA-MB-231 and 
4T1 cells seeded in 6-well plates were transfected with 
Lipofectamine 2000 (Invitrogen) when the cells were 
nearly 70% confluent. Then 100 pmol of pre-miR-200c 
was added. 6 h later, changed the culture medium to 
DMEM supplemented with 2% fetal bovine serum (FBS). 
24 h or 48 h after the transfection, harvested the cells for 
the isolation of total RNA or protein.
Recombinant vector
Recombinant lentiviruses containing miR-200c 
precursor or scramble sequences were purchased from 
SunBio (Shanghai, China). pReceiver-M02-KRAS 
(a mammalian expression plasmid) designed to specially 
express the human KRAS’ full-length open reading 
frame (ORF) without the miR-200c-responsive 3′-UTR 
was purchased from GeneCopoeia (Germantown, USA). 
An empty plasmid was served as a negative control. 
Overexpression plasmid was transfected into MDA-
MB-231 and 4T1 cells by Lipofectamine 2000 (Invitrogen) 
following the manufacturer’s instructions. 24 h or 48 h 
after transfection, total RNA or protein was isolated 
respectively. The expression levels of KRAS mRNA and 
protein were evaluated by qRT-PCR and Western blotting.
Luciferase reporter assay
The full-length of 3′-UTRs of the KRAS gene 
was amplified by PCR from MDA-MB-231 genomic 
DNA and inserted into pGL3 control vector (Promega, 
WI). Using the QIAGEN XL-site directed Mutagenesis 
Kit (QIAGEN, CA), we generated several inserts by 
deletions of 4 bp from the perfectly complementarity 
site of KRAS gene. According to the manufacturer’s 
instructions (solution V, programme T-016), MDA-
MB-231 cells were cotransfected with 0.5 ug firefly 
luciferase report vector and 0.5 ug control vector 
containing Renilla luciferase, pRL-TK (Promega) by nucl
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eoporation(AmaxaBiosystems). Each nucleoporation used 
50 nM of the miR-200c or a scrambled oligonucleotide. 
48 hours after transfection, the relative luciferase activities 
(RLA) of Firefly and Renilla were consecutively measured 
through the dual luciferase assay (Promega).
Protein isolation and western blotting
Protein was extracted fromMDA-MB-231 and 
4T1 cells lines by RIPA lysis buffer with proteinase 
inhibitor. By Protein BCA Assay Kit (Bio-Rad, USA), 
the concentration of protein in the lysates was measured. 
Each lane was loaded with 20 μg protein mixed with 
2 × SDS loading buffer. The protein was separated by 
12% SDS-polyacrylamide gel electrophoresis, and then 
transferred to polyvinylidenedifluoride membranes 
(Millipore, USA). The membranes were incubated with 
5% skim milk powder at room temperature for 1 h to block 
nonspecific binding. Subsequently, the membranes were 
incubated with antiserum containing antibodies against 
KRAS (F234), AKT(sc-1619), p-AKT (sc-33437), ERK 
(sc-292838) and p-ERK (sc-32577) which were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA) at 4°C 
for 12 h. To visualize the target proteins, a 1:5000 dilution 
of peroxidase-conjugated secondary antibody and ECL 
Western blotting detection reagents (ECL New England 
Biolabs, USA) were used. A Bio Image Intelligent 
Quantifier 1-D was used to quantify (Version 2.2.1, Nihon-
BioImage Ltd., Japan). Also an anti-β-actin antibody as a 
protein loading control (Boster, Wuhan, China) was used.
Cell proliferation assay
Cell viability analysis was preformed according 
to the methods using 3-(4, 5-Dimethylthiazol)-2, 
5-Diphenyltetrazolium Bromide [38]. To assess the 
incorporation of BrdUrd, MDA-MB-231 and 4T1 cells 
in treated and control term were incubated with 10 nM 
BrdUrd contained culture media for 16 h, then the cells 
were fixed with cold methanol and acetone (1:1).
Survival foci formation assay
Cells in exponential growth phase were plated into a 
six-well plate at 2000 cells/well and treated with miRNA 
after adhesion. When most cell clones had reached >50 
cells, they were stained with 0.06% crystal violet, and foci 
number was counted.
Mouse xenograft model
As previously described [39], the breast cancer 
model in BALC/c mice was established. 2 × 105 4T1 
cells infected with miR-200c precursoror scramble were 
inoculated subcutaneously into the dorsal flanks of mice 
(five in each group). Every four days the tumor size was 
measured. 28 days later, we killed the mice and performed 
necropsies. Then the tumors were weighed. The tumor 
volumes were calculated following the formula: A × B2/2 
(A: the largest diameter, B: the diameter perpendicular 
to A). All the procedures involved were performed 
following institutional guidelines.
Statistical analysis
All the images of Western blotting assay were 
the representative of at least three times independent 
experiments. qRT-PCR, the luciferase reporter, survival 
foci formation and cell proliferation assay were performed 
in triplicate. Each experiment was repeated for several 
times and the results were presented as the means ± SE. 
Statistical analysis was analyzed with a Student’s t-test. 
According to the Kaplan-Meier method, Overall survival 
(OS) and disease free survival (DFS) curves were plotted. 
The significance level was set as p < 0.05 level. All 
the statistical analysis was accomplished by the SPSS 
17.0 software.
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